Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma founder to chair Glide Pharma

Bryan Morton replaces Mark Kirby

Glide-Pharma-Bryan-MortonGlide Pharma has appointed Bryan Morton as its new non-executive chairman.

Morton replaces Mark Kirby at the UK-based company, which focuses on developing treatments that use its solid dose injector platform for administration.

Morton was most recently chief executive at oncology specialist EUSA Pharma – a company he also founded. EUSA was sold to Jazz Pharmaceuticals in 2012 for $700m.

His other entrepreneurial experience in the industry includes founding Zeneus Pharma, which was acquired by Cephalon for $360m.

Other previous positions held by Morton include president of Convatec EMEA, as well as a string of senior roles during a 20-year career at Merck & Co.

“His significant experience of building successful pharmaceutical companies will prove invaluable as Glide begins its next stage of development,” said Kirby on the appointment of his successor.

Commenting on the future of Glide Pharma under his direction Morton said: "Having completed a significant investment round earlier this year and winning a large funding award from the UK Biomedical Catalyst, the company is well positioned, and I look forward to helping the team exploit the value of Glide's unique technology.”

In addition to the appointment of Morton, Glide also announced that Dr Charles Potter is to step down from the board and his role as the company's chief business officer.

10th October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics